PhoP-regulated VirK acts as an accessory factor to maintain virulence in polymyxin-resistant Klebsiella pneumoniae
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkag290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Haibin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Peking University People's Hospital, Beijing, 100044, China. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Bacterial Proteins, Polymyxins, Drug Resistance, Bacterial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Postdoctoral Fellowship Program of CPSF.
Abstract (Originalsprache)
The genetic connection between virulence and antibiotic resistance remains poorly understood. Our previous RNA-Seq analysis of a polymyxin-resistant Klebsiella pneumoniae ATCC BAA2146 mutant identified a highly expressed VirK/YbjX family gene (kpn2146_RS17285), encoding a conserved membrane protein, designated virK (virulence required for Klebsiella pneumoniae). While PhoP-dependent antibiotic resistance is mediated through established pathways such as arn/pmr, we identify VirK as a PhoP-regulated factor specifically contributing to virulence. VirK localizes to the outer membrane and, although not involved in lipopolysaccharide modification, its deletion modestly reduced bacterial virulence in a mouse systemic infection model. Transcriptional and electrophoretic mobility shift assays demonstrated that virK is directly activated by the PhoP protein. A strong positive correlation between virK and phoP expression (r = 0.98) was also observed in multidrug-resistant clinical isolates. Since the PhoP/PhoQ two-component system mediates polymyxin resistance, its direct regulation of VirK uncovers an adaptive mechanism coupling enhanced virulence with antibiotic resistance. These findings reveal a previously unrecognized PhoP/VirK regulatory pathway that contributes to pathogenicity in polymyxin-resistant Klebsiella pneumoniae, offering new insights into bacterial evolution and suggesting that targeting PhoP/PhoQ could provide an effective strategy to combat multidrug-resistant K. pneumoniae infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Peking University People's Hospital, Beijing, 100044, China.
- Beijing Key Laboratory of Technology and Application for Anti-infective New Drugs Research and Development, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beiji…
- State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.
- Institute of Medical Technology, Peking University Health Science Center, Beijing, 100191, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Postdoctoral Fellowship Program of CPSF
Zitieren
APA
Li, H., Jin, L., Wang, P., Wang, R., Wang, Q., Wang, X., Li, C., You, X., & Wang, H. (2026). PhoP-regulated VirK acts as an accessory factor to maintain virulence in polymyxin-resistant Klebsiella pneumoniae. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag290
Vancouver
Li H, Jin L, Wang P, Wang R, Wang Q, Wang X, et al. PhoP-regulated VirK acts as an accessory factor to maintain virulence in polymyxin-resistant Klebsiella pneumoniae. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag290
BibTeX
@article{Li2026,
author = {Li, Haibin and Jin, Longyang and Wang, Penghe and Wang, Ruobing and Wang, Qi and Wang, Xiukun and Li, Congran and You, Xuefu and Wang, Hui},
title = {PhoP-regulated VirK acts as an accessory factor to maintain virulence in polymyxin-resistant Klebsiella pneumoniae},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag290}
}
EUVIMED